Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers
Sponsor: Chinook Therapeutics, Inc.
Terminated
Sponsor decision
Other terminated trials from Chinook Therapeutics, Inc.
More terminations from Chinook Therapeutics, Inc.
A PHASE1 clinical study on Healthy Volunteers, this trial is terminated or withdrawn. The trial is conducted by Chinook Therapeutics, Inc. and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Jun 2023 — Dec 2023 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Feb 2023 — Jun 2023 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinook Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .